The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment.
about
Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations.The implementation of tobacco-related brief interventions in substance abuse treatment: a national study of counselorsStructural and cultural barriers to the adoption of smoking cessation services in addiction treatment organizations.Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizationsSubstance abuse treatment counselors and tobacco use: a comparison of comprehensive and indoor-only workplace smoking bansSmoking Cessation Services in Adolescent Substance Abuse Treatment: Opportunities Missed?Adoption and implementation of medications in addiction treatment programs.Assessment and treatment of co-occurring eating disorders in privately funded addiction treatment programs.Adopting evidence-based medically assisted treatments in substance abuse treatment organizations: roles of leadership socialization and funding streamsBarriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure.Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findingsThe implementation of smoking cessation counseling in substance abuse treatmentPhysicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations.Assessing Adolescent Substance Abuse Programs with Updated Quality Indicators: The Development of a Consumer Guide for Adolescent TreatmentPerceptions of the state policy environment and adoption of medications in the treatment of substance use disorders.Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.State policy influence on the early diffusion of buprenorphine in community treatment programsSustainment of smoking cessation programs in substance use disorder treatment organizations.Adolescent-only substance abuse treatment: availability and adoption of components of qualityResearch on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.Availability of HIV-related health services in adolescent substance abuse treatment programs.Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions.A demonstration project implementing extended-release naltrexone in Los Angeles County.Prescribed Psychotropic Medication Use in Patients Receiving Residential Addiction Treatment.
P2860
Q33803543-CE245FE0-AF03-402A-9812-9E52F58DF0C7Q33830328-5057A6BE-4586-4812-A41E-115F63557CF7Q34070104-22E5613A-AFB8-4974-8D54-34B9396C2CAAQ34111054-6D5A057F-BA43-4883-A540-8D333A05835BQ34245034-E87A5395-1BC5-4501-BFD6-9E3FBEE41130Q34528070-83FDC3A9-9E44-4F27-93F1-6EE79EB5C1DDQ34607338-0F8D7DD5-1BBC-4D33-AD44-609F2D2D7E45Q34789587-0038AD68-559D-4848-8951-7B11D6F068E9Q34806644-18A3E589-4B8B-4981-84D6-4FDB60388723Q35042742-84F36266-A7D3-4873-A6CD-3D23EF9D007CQ35178476-739C9A94-7FAF-4D8A-A985-5E30C9F656DAQ35291386-42F55697-4E3F-49D2-8BBE-51A4FEEE203BQ35937004-6437DF80-078F-45F1-B235-3BC09939F26AQ36093339-73E0DE6D-B24F-40B6-BCF9-B9558B5E4358Q36192673-7BE071FA-3809-447B-9521-E12590251436Q36597560-099DC123-998D-4D06-86D3-B0CA79D0B34BQ36766544-3073BE60-482D-4B74-91E3-E7E89284563FQ36823244-BF63F0DE-059A-40AD-B48C-0368D193B478Q37216771-15E57D83-F9BE-4DFF-A45A-4910F8FB297FQ37224883-003F6A2B-C7BA-419A-8889-CA62C59AF03EQ37379678-02773B1F-646B-4ADD-802D-C104EED3501CQ37443969-C53D2628-4338-4F99-A67D-23A86CDE3FEEQ38986525-16A92BC6-BF8B-42BB-A50C-BA6FC418FCA6Q39789791-D53C20F2-7B46-4434-BF52-7775FDB3A308
P2860
The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The use of antidepressant medi ...... tibility, and the environment.
@en
type
label
The use of antidepressant medi ...... tibility, and the environment.
@en
prefLabel
The use of antidepressant medi ...... tibility, and the environment.
@en
P2093
P2860
P1476
The use of antidepressant medi ...... tibility, and the environment.
@en
P2093
Hannah K Knudsen
Lori J Ducharme
Paul M Roman
P2860
P304
P356
10.1177/002214650704800207
P577
2007-06-01T00:00:00Z